C07C321/26

Additive for imparting ultraviolet absorbency and/or high refractive index to matrix, and resin member using same

Provided is an additive for imparting ultraviolet absorbency, or an additive for imparting a high refractive index, which has satisfactory compatibility with a resin serving as a matrix and can maintain high transparency even if added in high concentrations. Also provided is an additive with which the function of imparting both ultraviolet absorbency and a high refractive index can be realized by means of one kind of additive. This additive is represented by the following Formula (I): ##STR00001## wherein at least one of R.sup.1a to R.sup.9a is a monovalent sulfur-containing group represented by the following Formula (i-1) or Formula (i-2): ##STR00002## wherein R.sup.10a to R.sup.12a each represent a divalent hydrocarbon group or the like; and R.sup.13a represents a monovalent hydrocarbon group or the like.

Additive for imparting ultraviolet absorbency and/or high refractive index to matrix, and resin member using same

Provided is an additive for imparting ultraviolet absorbency, or an additive for imparting a high refractive index, which has satisfactory compatibility with a resin serving as a matrix and can maintain high transparency even if added in high concentrations. Also provided is an additive with which the function of imparting both ultraviolet absorbency and a high refractive index can be realized by means of one kind of additive. This additive is represented by the following Formula (I): ##STR00001## wherein at least one of R.sup.1a to R.sup.9a is a monovalent sulfur-containing group represented by the following Formula (i-1) or Formula (i-2): ##STR00002## wherein R.sup.10a to R.sup.12a each represent a divalent hydrocarbon group or the like; and R.sup.13a represents a monovalent hydrocarbon group or the like.

Material for forming film for lithography, composition for forming film for lithography, film for lithography, pattern forming method and purification method

The material for forming a film for lithography according to the present invention contains a compound represented by the following formula (1): ##STR00001##
wherein, each R.sup.0 independently represents a monovalent group having an oxygen atom, a monovalent group having a sulfur atom, a monovalent group having a nitrogen atom, a hydrocarbon group or a halogen atom, and each p is independently an integer of 0 to 4.

Material for forming film for lithography, composition for forming film for lithography, film for lithography, pattern forming method and purification method

The material for forming a film for lithography according to the present invention contains a compound represented by the following formula (1): ##STR00001##
wherein, each R.sup.0 independently represents a monovalent group having an oxygen atom, a monovalent group having a sulfur atom, a monovalent group having a nitrogen atom, a hydrocarbon group or a halogen atom, and each p is independently an integer of 0 to 4.

COMPOUND FOR CAPPING LAYER AND ORGANIC LIGHT EMITTING DEVICE INCLUDING SAME

A novel compound for a capping layer, and an organic light-emitting device containing the same are disclosed.

COMPOUND FOR CAPPING LAYER AND ORGANIC LIGHT EMITTING DEVICE INCLUDING SAME

A novel compound for a capping layer, and an organic light-emitting device containing the same are disclosed.

1,6-NAPHTHALENEDITHIOL PRODUCT AND PROCESS FOR PRODUCING THE SAME

Provided are a naphthalenedithiol (or a naphthalenedithiol product) having a high purity and a reduced coloration, and a process for producing the same.

A 1,6-naphthalenedithiol (a 1,6-naphthalenedithiol product) according to the present invention has a purity of not less than 99.5% and a polymeric 1,6-naphthalenedithiol content of not more than 0.2%, each determined by high performance liquid chromatography using area normalization; and has a Gardner color scale in a molten state of not more than 1. The polymeric 1,6-naphthalenedithiol may be a disulfide form as a dimeric 1,6-naphthalenedithiol. Such a 1,6-naphthalenedithiol product can be produced by distilling a crude raw material containing 1,6-naphthalenedithiol and at least a polymeric 1,6-naphthalenedithiol to obtain a distillate fraction containing 1,6-naphthalenedithiol. The crude raw material may be a dry solid of a crudely purified product of 1,6-naphthalenedithiol from a reaction mixture.

1,6-NAPHTHALENEDITHIOL PRODUCT AND PROCESS FOR PRODUCING THE SAME

Provided are a naphthalenedithiol (or a naphthalenedithiol product) having a high purity and a reduced coloration, and a process for producing the same.

A 1,6-naphthalenedithiol (a 1,6-naphthalenedithiol product) according to the present invention has a purity of not less than 99.5% and a polymeric 1,6-naphthalenedithiol content of not more than 0.2%, each determined by high performance liquid chromatography using area normalization; and has a Gardner color scale in a molten state of not more than 1. The polymeric 1,6-naphthalenedithiol may be a disulfide form as a dimeric 1,6-naphthalenedithiol. Such a 1,6-naphthalenedithiol product can be produced by distilling a crude raw material containing 1,6-naphthalenedithiol and at least a polymeric 1,6-naphthalenedithiol to obtain a distillate fraction containing 1,6-naphthalenedithiol. The crude raw material may be a dry solid of a crudely purified product of 1,6-naphthalenedithiol from a reaction mixture.

SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS OF SSAO AND USES THEREOF

The present invention is related to the preparation and pharmaceutical use of substituted 3-haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification:

##STR00001##

The invention also relates to methods of using compounds of Formula I, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases, ocular diseases, fibrotic diseases, diabetes-induced diseases and cancer.

SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS OF SSAO AND USES THEREOF

The present invention is related to the preparation and pharmaceutical use of substituted 3-haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification:

##STR00001##

The invention also relates to methods of using compounds of Formula I, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases, ocular diseases, fibrotic diseases, diabetes-induced diseases and cancer.